Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16

Vaccine

Volumn 21, Issue 9-10, 2003, Pages 891-896

  Bubeník, Jan ^a   Mikyšková, Romana ^a   Vonka, Vladimír ^b   Mendoza, Luis ^a   Šímová, Jana ^a   Šmahel, Michal ^b   Indrová, Marie ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Dendritic cells; HPV 16; Interleukin 2

Indexed keywords

INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT INTERLEUKIN 2; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONFERENCE PAPER; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; HAPLOTYPE; INOCULATION; MALE; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR VOLUME; VIRUS CARCINOGENESIS; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; INTERLEUKIN-2; MALE; MICE; MICE, INBRED C57BL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; TUMOR VIRUS INFECTIONS;

EID: 0037435981     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00537-6     Document Type: Conference Paper

References (31)

1. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta. 1288:1996;F55-78.
2. Walboomers J.M., Jacobs M.V., Manos M.M.et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1999;12-19.
3. Cornelison T.L. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment. Curr. Opin. Oncol. 12:2000;466-473.
4. Ling M., Kanayama M., Roden R., Wu T.C. Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J. Biomed. Sci. 7:2000;341-356.
5. Bubeník J. Animal models for development of therapeutic HPV 16 vaccines. Int. J. Oncol. 20:2002;207-212.
6. Lin Z., Ghai J., Ostrow R.S., Faras A.J. The expression levels of the human papillomavirus type 16 E7 correlate with its transforming potential. Virology. 202:1995;260-270.
7. Galloway D.A., McDougall J.K. The disruption of cell cycle checkpoints by papillomavirus oncoprotein contributes to anogenital neoplasia. Semin. Cancer Biol. 7:1996;309-315.
8. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92:2000;690-698.
9. Connor M.E., Stern P.L. Loss of MHC class I expression in cervical carcinomas. Int. J. Cancer. 46:1990;1029-1034.
10. Garrido F., Ruiz-Cabello F., Cabrera T.et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today. 18:1997;89-95.
11. Hicklin D.J., Marincola F.M., Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today. 5:1999;178-186.
12. Šmahel M., Sobotková E., Bubeník J.et al. Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer. 84:2001;374-380.
13. Liu K.Y., Guarnieri F.G., Staveley-O'Carroll K.F.et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21-26.
14. Klein G., Sjögren H.O., Klein E., Hellström K.E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20:1960;1561-1572.
15. Klein G., Klein E. Antigenic properties of other experimental tumours. Cold Spring Harbor Symp. Quant. Biol. 27:1962;463-470.
16. Bubeník J., Šímová J., Hájková R.et al. Interleukin-2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int. J. Oncol. 14:1999;593-597.
17. Bubeník J., Šímová J., Vonka V., Šmahel M., Mikyšková R., Mendoza L. Dendritic cell-based vaccines for therapy of HPV 16-induced tumours. Adv. Exp. Med. Biol. 495:2001;359-362.
18. Mikyšková R., Bubeník J., Mendoza L.et al. Local cytokine treatment of HPV 16-associated tumours results in inhibition of their lung metastases. Clin. Exp. Metastasis. 18:2001;581-587.
19. Bubeník J., Indrová M., Němečková Š.et al. Solubilized tumour-associated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitisation of lymph node cells. Int. J. Cancer. 21:1978;348-355.
20. Rössner P., Bubeník J., Indrová M.et al. Genetically modified tumour vaccines: insertion of the IL-2 gene downregulates tumorigenicity more efficiently than insertion of the CD80 gene. Int. J. Oncol. 10:1997;77-82.
21. Kearney J.F., Radbruch A., Liesegang B., Rajewski K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123:1979;1548-1550.
22. Karasuyama H., Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin-2, 3, 4 or 5, using modified cDNA expression vectors. Eur. J. Immunol. 18:1988;97-104.
23. - tumours of HPV 16 origin. Int. J. Oncol. 20:2002;643-646.
24. Mendoza L., Indrová M., Hájková R.et al. Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth. Folia Biol. (Praha). 46:2000;91-97.
25. Vlk V., Rössner P., Indrová M.et al. Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int. J. Cancer. 76:1998;115-119.
26. Kedar E., Klein E. Cancer immunotherapy: are the results discouraging? Can they be improved? Adv. Cancer Res. 59:1992;245-322.
27. Melief C.J.M., Toes R.E.M., Medema J.P.et al. Strategies for immunotherapy of cancer. Adv. Immunol. 75:2000;235-282.
28. Bubeník J., Den Otter W., Huland E. Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines. Cancer Immunol. Immunother. 49:2000;116-122.
29. Huang A.V.C., Golumbek P., Ahmadzadeh M.et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumour antigens. Science. 264:1994;961-965.
30. Bubeník J. Gene transfer for immunotherapy of cancer. Gene Ther. 3:1996;944-945.
31. Bubeník J. Utilisation of oncoprotein-pulsed dendritic cells as tumour vaccines. J. Cancer Res. Clin. Oncol. 127:2001;463-466.